Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at
Wall Street
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)